Hypervolemic-Hemodilution and Hypertension During Temporary Middle Cerebral Artery Occlusion in Rats: The Effect on Blood-Brain Barrier Permeability

Daniel J. Cole, John C. Drummond, Jerry S. Matsumura, Suzzanne Marcantonio and Bonnie I. Chi-Lum

ABSTRACT: The effect of hypervolemic-hemodilution, with and without hypertension, on blood-brain barrier permeability was investigated in rats, after 180 minutes of middle cerebral artery occlusion (MCAo), and 60 minutes of reperfusion. One of the following conditions was maintained during MCAo: 1) Control — hematocrit and blood pressure were not manipulated; 2) Hypervolemic-Hemodilution/Normotension — the hematocrit was decreased to 30%; 3) Hypervolemic-Hemodilution/Hypertension — the hematocrit was decreased to 30% and mean arterial pressure increased by 30 mmHg with phenylephrine. In all groups, Evans Blue was administered, and its concentration determined by spectrophotometric assay. Evans Blue (ng (g⁻¹ of brain tissue [mean ± SD]) was greater in the Hypervolemic-Hemodilution/Hypertension group (71 ± 20) versus the Control (13 ± 9) and Hypervolemic-Hemodilution/Normotension (17 ± 10) groups (p < 0.05). No other differences were present. These results support the hypothesis that during MCAo, hypervolemic-hemodilution/hypertensive therapy effects an increase in blood-brain barrier permeability in the early period of reperfusion.

Physiologic manipulations such as hemodilution, hypervolemia, and hypertension, which improve cerebral blood flow (CBF), have nonetheless had variable success on outcome following focal cerebral ischemia. Physiologic manipulations such as hemodilution, hypervolemia, and hypertension, which improve cerebral blood flow (CBF), have nonetheless had variable success on outcome following focal cerebral ischemia.¹⁻⁸ One possible explanation for this variability is that in spite of augmenting CBF, these therapies might detrimentally contribute to injury processes that secondarily worsen the original injury (e.g., cerebral edema).⁹⁻¹⁰ Previous studies in our laboratory have shown that during middle cerebral artery occlusion (MCAo) in rats, hypervolemic-hemodilution/hypertensive (H-H/HTN) therapy effects an increase in CBF to ischemic brain areas, and a decrease in cerebral injury and brain water content following temporary MCAo.¹¹⁻¹³ Accordingly, it was postulated that a primary mechanism whereby H-H/HTN therapy decreases brain water content is by reducing the cytotoxic component of ischemic cerebral edema.¹¹⁻¹³ In the early period of permanent cerebral ischemia, edema is predominantly effected by cytotoxic mechanisms.¹⁴⁻¹⁵ However, in the event of reperfusion, edema can be influenced by both cytotoxic and vasogenic (blood-brain barrier permeability)
properties.\textsuperscript{14,15} Thus, in our model of temporary MCAo\textsuperscript{11} we considered it possible that H-H/HTN therapy might exert a detrimental effect on blood-brain barrier permeability that was obscured by an overwhelmingly positive effect on cytotoxic edema formation.

There is evidence suggesting that hypertension, per se, may disrupt the blood-brain barrier.\textsuperscript{16-18} The manifestation of blood-brain barrier disruption, due to hypertensive treatment during a period of temporary focal cerebral ischemia, might be paramount during the early period of reperfusion when the vasculature is suddenly exposed to increases in intraluminal pressure.\textsuperscript{19} Such a concern might pertain to the clinical situation in which thrombolytic therapy is considered.\textsuperscript{20} During a diagnostic delay, therapeutic goals might include minimizing the existing injury without exacerbating secondary injury (e.g., vasogenic edema). The present study was designed to determine if H-H/HTN therapy, employed during temporary MCAo, affects blood-brain barrier permeability in the early period of reperfusion.

**Materials and Methods**

The protocol was reviewed and approved by the Animal Research Committee of Loma Linda University under the animal care guidelines of the United States Department of Health and Human Services. Male, Spontaneously Hypertensive Rats (350-400 grams) were anesthetized with isoflurane, oro-tracheally intubated, and mechanically ventilated with a Harvard Rodent Respirator (Harvard Apparatus Co., Boston, MA). The isoflurane concentration was maintained at 1.44% end-tidal during the preparatory and study period. The femoral vessels were cannulated for blood pressure monitoring, blood sampling, and fluid and drug administration. Sodium chloride (0.9%) was administered at a rate of 4 ml-kg\textsuperscript{-1}·hour\textsuperscript{-1}. Physiologic monitoring included mean arterial pressure (MAP), pH, PaCO\textsubscript{2}, PaO\textsubscript{2}, serum glucose, and hematocrit. Rectal temperature was servo-controlled at 37°C with a heating blanket. Physiologic values were recorded every fifteen minutes and reported as an average over the MCAo and reperfusion period.

The left middle cerebral artery was exposed via a small subtemporal craniectomy. Each rat was randomly assigned one of the following treatments which was implemented immediately prior to, and maintained during MCAo:

- **Control (n = 8).** Neither hematocrit, blood volume, nor MAP were manipulated.
- **Hypervolemic-Hemodilution (H-H, n = 8).** Five per cent human albumin (Travenol Laboratories, Glendale, CA) was administered to maintain a hematocrit of 29-32%.
- **H-H/Hypertension (H-H/HTN, n = 8).** Hypervolemic-hemodilution was achieved in a fashion identical to the H-H group, and MAP increased by 30 mmHg above baseline with an infusion of phenylephrine.

The middle cerebral artery was then occluded with 10-0 monofilament nylon suture in two locations for 180 minutes. The first location was just proximal to the lenticulostriate arterial branch. The second location was distal to the intersection of the middle cerebral artery with the inferior cerebral vein. In this manner, consistent injury to the basal ganglia and cortex has been achieved in previous studies.\textsuperscript{11,13} After 180 minutes of MCAo, the sutures were released and a 60 minute period of reperfusion allowed. Hematocrit, blood volume, and MAP were not manipulated during the reperfusion period.

A surgical sham group was prepared by maintaining five rats in a manner identical to the H-H/HTN group (i.e., 180 minutes of hypervolemic-hemodilution and hypertension), with the exception that the suture was passed, but not tightened around the middle cerebral artery (i.e., ischemia was not induced).

Thirty minutes after ligature release, 1 ml-kg\textsuperscript{-1} body weight of 3% Evans Blue was injected intravenously and allowed to circulate for 30 minutes. This dose provided for equivalent serum concentrations of Evans Blue between groups, and was totally bound to serum albumin as determined by reacting rat serum with trichloroacetic acid.\textsuperscript{21} After the 30 minute period of Evans Blue circulation, the animals were euthanized, and the amount and area of Evans Blue was determined in the hemisphere ipsilateral to MCAo by spectrophotometry and image analysis. Briefly described, the descending aorta was cross-clamped and Evans Blue was cleared from the vascular space by aortic perfusion of 0.9% NaCl at 37°C (100 ml). The brains were removed and coronally sectioned 3.0, 5.0, and 7.0 mm from the frontal pole (see Figure 1). Each coronal segment was divided into hemispheres and immersed for 72 hours in 100% Formamide Reagent (Fisher Scientific, Los Angeles, CA) at a ratio of 1 ml-100 mg\textsuperscript{-1} of brain tissue. After 72 hours, the optical density of the Evans Blue/formamide diluent was determined using a Hitachi 100-80 Computerized Spectrophotometer (Hitachi Instruments Inc., San Jose, CA) set at an absorbance wave length of 620 nm. The concentration of Evans Blue in each hemisphere.

**Figure 1** — Coronal brain sections in which the area of Evans Blue extravasation was determined. Section 1 was 3.0 mm posterior to the frontal pole. Section 2 was 5.0 mm posterior to the frontal pole. Section 3 was 7.0 mm posterior to the frontal pole. See text for further explanation.
was determined by reference to a regression curve derived from Evans Blue/formamide standards. The change in blood-brain barrier permeability due to MCAo was then calculated by subtracting the amount of Evans Blue in the hemisphere contralateral to MCAo from the amount of Evans Blue in the hemisphere ipsilateral to MCAo.

Image analysis of the area of Evans Blue extravasation in brain tissue was determined by taking photographs of each corona surface (3.0, 5.0, and 7.0 mm from the frontal pole) immediately before formamide extraction (Kodak Ektachrome, tungsten 160 ASA). The pictures were analyzed by an independent observer who was blinded to the study protocol, using a Drexel/DUMAS Image Analyzer in order to determine the area of Evans Blue extravasation.

Statistical analysis was performed on the physiologic and Evans Blue data using an analysis of variance, and as appropriate, mean values were compared by t-tests with a Bonferroni correction for multiple comparisons. All values are reported as mean ±SD. A p value of less than 0.05 was considered significant.

RESULTS

During the occlusion period there were no between groups differences in pH, PaCO₂, PaO₂, and serum glucose. There were differences in hematocrit and MAP (see Table 1). The average phenylephrine dose required to maintain a MAP increase of 30 mmHg in the H-H/HTN group was 18 ± 4 mg·kg⁻¹·min⁻¹. During reperfusion there were no between groups differences in pH, PaCO₂, PaO₂, and MAP (see Table 1). However, during reperfusion there were differences in hematocrit and serum glucose (see Table 1).

The amount of Evans Blue (μg·g⁻¹ of brain tissue) that crossed the blood-brain barrier to albumin was determined by reference to MCAo. In previous studies this area is ~35-40% of the hemisphere, with a variance (SD) of 9-12%. The dashed line defines the area of Evans Blue extravasation. In general, this area was confined to the cerebral cortex. However, for three animals in the H-H/HTN group Evans Blue extravasated into the sub-cortex.

Table 1: Physiologic Data (mean ± SD)
H-H is the hypervolemic-hemodilution group. H-H/HTN is the group that received both hypervolemic-hemodilution and phenylephrine-induced hypertension.

<table>
<thead>
<tr>
<th></th>
<th>Occlusion Period</th>
<th>Reperfusion Period</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>H-H</td>
</tr>
<tr>
<td>pH (units)</td>
<td>7.41 ± 0.03</td>
<td>7.42 ± 0.02</td>
</tr>
<tr>
<td>PaO₂ (mmHg)</td>
<td>144 ± 23</td>
<td>155 ± 23</td>
</tr>
<tr>
<td>PaCO₂ (mmHg)</td>
<td>39.1 ± 1.6</td>
<td>38.7 ± 1.3</td>
</tr>
<tr>
<td>Hematocrit (%)</td>
<td>44 ± 3</td>
<td>30 ± 1*</td>
</tr>
<tr>
<td>MAP (mmHg)</td>
<td>132 ± 3</td>
<td>124 ± 6*</td>
</tr>
<tr>
<td>Glucose (mg·dl⁻¹)</td>
<td>116 ± 26</td>
<td>114 ± 17</td>
</tr>
</tbody>
</table>

|                          | H-H              | H-H/HTN           |
| pH (units)               | 7.39 ± 0.03      | 7.42 ± 0.04       | 7.39 ± 0.04      |
| PaO₂ (mmHg)              | 146 ± 29         | 140 ± 18          | 137 ± 30         |
| PaCO₂ (mmHg)             | 38.2 ± 2.5       | 37.0 ± 2.2        | 36.6 ± 2.3       |
| Hematocrit (%)           | 40 ± 3           | 29 ± 1*           | 30 ± 3*          |
| MAP (mmHg)               | 120 ± 14         | 123 ± 10          | 121 ± 5          |
| Glucose (mg·dl⁻¹)        | 119 ± 17         | 117 ± 10          | 86 ± 12†         |

*p < 0.05 versus the Control group.
†p < 0.05 versus the Control and H-H groups.
Table 3: The Percentage of the Hemisphere Ipsilateral to the Occluded Middle Cerebral Artery with Evans Blue Extravasation (mean ± SD) in Coronal Sections 3.0, 5.0, and 7.0 mm Posterior to Occluded Middle Cerebral Artery with Evans Blue Extravasation

<table>
<thead>
<tr>
<th>Section</th>
<th>Control</th>
<th>H-H</th>
<th>H-H/HTN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section 1</td>
<td>8.7 ± 2.6</td>
<td>7.5 ± 2.6</td>
<td>14.5 ± 5.6*</td>
</tr>
<tr>
<td>Section 2</td>
<td>7.3 ± 2.6</td>
<td>8.5 ± 2.6</td>
<td>14.3 ± 5.1*</td>
</tr>
<tr>
<td>Section 3</td>
<td>4.2 ± 2.3</td>
<td>5.9 ± 2.1</td>
<td>6.8 ± 2.2+</td>
</tr>
</tbody>
</table>

*p < 0.05 versus the Control and H-H groups.
+fp < 0.05 versus the Control group.

increased. This is consistent with a hypothesis that although H-H/HTN therapy augments CBF, and decreases brain injury and cytotoxic cerebral edema;1-11 such therapy conveys a risk of worsening vasogenic edema which might detrimentally affect ischemic injury.15

Notable physiologic differences include an 8 mmHg reduction in MAP during MCAo in the H-H group compared to the Control group. In addition, there was a decrease in serum glucose for the H-H/HTN group during reperfusion. We have observed this effect in a previous study,11 and postulate it to be due to a rebound phenomenon mediated at pancreatic α-adrenergic receptors when discontinuing the α-adrenergic agonist phenylephrine.24 If this difference (=30 mg·dl⁻¹) had any effect on blood-brain barrier function, it is likely to have improved the ischemic state in the H-H/HTN group, and underestimated the detrimental effect of H-H/HTN therapy on blood-brain barrier permeability.25

In the present study blood-brain barrier permeability was assessed by the indicator dye Evans Blue (molecular weight-961 daltons), which binds to albumin (molecular weight =68,500 daltons) and does not normally cross the blood-brain barrier in appreciable amounts.21,22 We assessed cerebral Evans Blue by two methods that address unique aspects of vasogenic edema. Spectrophotometry was used as a direct assessment of blood-brain barrier permeability to the Evans Blue:albumin complex, and an indirect indicator of vasogenic edema formation.15 In addition, the area of Evans Blue staining was determined by image analysis, which is suggestive of the spread of vasogenic edema and secondary injury.15 One critique of this methodology is that a major component of Evans Blue in the hemisphere ipsilateral to MCAo was intravascular, and not intraparenchymal. This seems unlikely for the following reasons: 1) Evans Blue in the hemisphere contralateral to MCAo and in sham animals was not appreciable amounts.21,22 2) in pilot studies, 100 ml of saline was more than twice the volume necessary to totally wash out Evans Blue from the cerebral venous effluent (measured by spectrophotometry), and 3) after identical perfusion fixation, light microscopy has revealed minimal areas in the hemisphere ipsilateral to MCAo with intravascular blood.26

Simplistically, the diffusion of a substance across a membrane depends on the concentration gradient, a membrane permeability factor, and membrane area. One characteristic of cerebral ischemia is a disintegration of the microvasculature, resulting in blood-brain barrier permeability changes that correlate with the magnitude of ischemic injury.27-29 Previous studies with similar models of focal cerebral ischemia in our laboratory have consistently demonstrated the ability of hypertension to decrease ischemic injury.11-13 As there were commensurate serum concentrations of Evans Blue in the three groups, it appears that the Evans Blue increase for the H-H/HTN group was a function of a change in membrane permeability effected by combined hypertensive/hypertensive therapy. It must be acknowledged that this is speculative as membrane permeability was not directly measured.

We were surprised that a treatment (H-H/HTN) which has been shown to reduce ischemic injury,11,13 aggravated blood-brain barrier leak to albumin. Furthermore, we did not expect that H-H/HTN therapy during a three hour period of vascular occlusion (when the blood-brain barrier is intact to serum albumin14) would have an appreciable affect on blood-brain barrier permeability to Evans Blue during a subsequent period of normotensive reperfusion. We consider the following hypotheses plausible explanations for the discrepancy between the previous reports of reduced area of ischemic injury achieved by H-H/HTN therapy,11,13 and the increase in Evans Blue leak reported in the present study.

The first hypothesis is that a reduction in Evans Blue leak due to decrease in area of blood-brain barrier injury was minor compared to the increase effected by H-H/HTN therapy in the remaining area of injury. In a variety of methodological settings, hypertension has resulted in blood-brain barrier disruption, presumably via increased intraluminal hydrostatic pressure.16-18,30-40 If blood-brain barrier disruption does occur due to hydrostatic pressure increases induced during MCAo, it might be maximally manifested during reperfusion, when the blood-brain barrier is prone to permeability changes.19 The second and related hypothesis, is that phenylephrine might exert similar intraluminal hydrostatic pressure increases in the arterial and venular beds. The following exaggerated example portrays such an event. All other factors being equal, if an apparent 30 mmHg increase in systemic MAP effects a 30 mmHg increase in arterial and venular intraluminal hydrostatic pressure, no net increase in CBF or, decrease in tissue and vascular injury should occur. However, there could be an increase in blood-brain barrier permeability due to the increase in intraluminal hydrostatic pressure. There is evidence in support of this theory.16,18,41,42 although the relative contribution by phenylephrine to each vascular bed is not known. Accordingly, this hypothesis remains highly speculative. The third hypothesis involves the direct effect adrenergic agents might have on vascular permeability.38,43 It has been demonstrated that α-adrenergic agents exert an effect on cerebral vascular permeability via a central noradrenergic regulating system. However, the extent to which this property might have been operative in the present study is not known.

With the evolution of thrombolytic stroke therapy, and consequent early reperfusion of ischemic brain; the entry of serum proteins into brain parenchyma, the accompanying vasogenic edema, and the detrimental effect edema has on ischemic injury15 may become of greater clinical importance. Although thrombolytic therapy has demonstrated an ability to ameliorate neurologic injury following focal cerebral ischemia,20 there is evidence to suggest that such therapy might convey a risk of ischemic brain edema.20,44 If thrombolytic therapy proves efficacious for human stroke, the clinician may have to care for patients during a diagnostic interval prior to treatment and reperfusion. Manipulation of hemorheology and perfusion pressure during this time may favorably affect primary injury by increas-
ing collateral flow through anastomotic channels, or via a redistribution of flow to pressure passive vascular areas.\textsuperscript{1,4,7,11,13} Notwithstanding, during the acute phase of reperfusion, Kuroiwa et al.\textsuperscript{19} have proposed that a “hemodynamic leak” of the blood-brain barrier occurs, which is associated with the sudden onset of intraluminal pressure and hyperemic CBF. It may be that there is a detrimental effect of H-H/HTN therapy on this “hemodynamic leak” which might influence therapeutic choices prior to the institution of thrombolysis. We acknowledge that the present study only suggests this possibility. It provides no insight into the question of whether the negative effects of H-H/HTN therapy outweigh the positive effects.

In summary, we evaluated the effect of hypervolemic-hemodilution and hypertension on blood-brain barrier permeability to Evans Blue following temporary MCAo. We observed an increase in both blood-brain barrier permeability to Evans Blue, and the area of Evans Blue accumulation in the brain by combined H-H/HTN therapy. These results support the hypothesis that although H-H/HTN therapy has demonstrated an ability to increase CBF and decrease primary brain injury in previous studies;\textsuperscript{1,11,13} such therapy may also convey a risk of worsening vasogenic edema during the period of reperfusion.

ACKNOWLEDGEMENTS

The authors gratefully acknowledge the technical assistance of Terrill Osborne; and Jackie Breyer in the preparation of this manuscript. This work was supported in part by a Research Starter Grant from the American Society of Anesthesiologists.

REFERENCES


